AI assistant
LIGAND PHARMACEUTICALS INC — Director's Dealing 2022
Dec 21, 2022
31289_dirs_2022-12-20_58289726-6047-4f6d-a7a8-d88883278b08.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2022-12-16
Reporting Person: HIGGINS JOHN L (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-12-16 | Common Stock | S | 10000 | $61.8657 | Disposed | 422984 | Direct |
Footnotes
F1: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on September 22, 2022, in accordance with Rule 10b5-1.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.08 to $63.055. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.